![logo](/logos/PHAT.webp)
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
17.72 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Phathom Pharmaceuticals, Inc. |
Symbool | PHAT |
Munteenheid | USD |
Prijs | 17.72 |
Beurswaarde | 1,210,091,712 |
Dividendpercentage | 0% |
52-weken bereik | 6.065 - 18.58 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Terrie J. Curran |
Website | https://www.phathompharma.com |
An error occurred while fetching data.
Over Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)